GS
APLS

GTS Securities’s Apellis Pharmaceuticals APLS Stock Holding History

GTS Securities’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,100
Closed -$205K – 1402
2024
Q3 		$205K Buy
+7,100
New +$263K ﹤0.01% 3631
2024
Q1 		– Sell
-117,600
Closed -$7.04M – 3814
2023
Q4 		$7.04M Sell
117,600
-78,900
-40% -$4M 0.01% 790
2023
Q3 		$7.47M Buy
+196,500
New +$8.63M 0.01% 725

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GTS Securities's APLS Position: Q1 2026 in Review

GTS Securities opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 15,604 shares worth $628K. The stake represents 0.02% of the portfolio and ranks #616 among its holdings. This is a return to the name: GTS Securities previously reported a position in APLS as recently as Q3 2024.

GTS Securities first reported a position in APLS in Q2 2023 and has held it in 7 quarters since. The position peaked at $3.12M in Q4 2023. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • GTS Securities held 15,604 shares of Apellis Pharmaceuticals worth $628K as of Q1 2026.
  • Apellis Pharmaceuticals was a new GTS Securities position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.02% of GTS Securities's portfolio in Q1 2026, its #616 holding.
  • GTS Securities first reported a position in Apellis Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • GTS Securities's Apellis Pharmaceuticals position peaked at $3.12M in Q4 2023.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.